Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours

Nils F. Schreiter, Winfried Brenner, Munenobu Nogami, Ralph Buchert, Alexander Huppertz, Ulrich Frank Pape, Vikas Prasad, Bernd Hamm, Martin H. Maurer

Research output: Contribution to journalArticlepeer-review

71 Scopus citations


Purpose: Although somatostatin receptor positron emission tomography (PET)/CT is gaining increasing popularity and has shown its diagnostic superiority in several studies, 111Indiethylenetriaminepentaacetic acid (DTPA)-octreotide is still the current standard for diagnosis of neuroendocrine tumours (NET). The aim of this study was to compare the costs for the two diagnostic tests and the respective consequential costs. Methods: From January 2009 to July 2009, 51 consecutive patients with enteropancreatic NET who underwent contrast-enhanced 68Ga-DOTATOC PET/CT (n=29) or 111In-DTPA-octreotide (mean 3 whole-body scans plus 1.6 low-dose single photon emission computed tomography/CT; n=22) were included. For cost analysis, direct costs (equipment) and variable costs (material, labour) per examination were calculated. Additionally required CT and/or MRI examinations within the staging process were assessed as consequential costs. An additional deterministic sensitivity analysis was performed. Results: A 68Ga-DOTATOC PET/CT examination yielded total costs (equipment, personnel and material costs) of 548 €. On the other hand, an 111In-DTPA-octreotide examination resulted in 827 € total costs. Costs for equipment and material had a share of 460 €/720 € for 68Ga-DOTATOC/ 111In-DTPA-octreotide and labour costs of 89 €/106 €. With 68Ga-DOTATOC additional MRI had to be performed in 7% of the patients resulting in a mean of 20 € for supplementary imaging per patient; 82% of patients with 111In-DTPA- octreotide needed additional MRI and/or CT resulting in mean additional costs of 161 € per patient. Conclusion: 68Ga-DOTATOC PET/CT was considerably cheaper than 111In-DTPA-octreotide with respect to both material and personnel costs. Furthermore, by using 68Ga-DOTATOC PET/CT considerably fewer additional examinations were needed reducing the consequential costs significantly.

Original languageEnglish
Pages (from-to)72-82
Number of pages11
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Issue number1
StatePublished - Jan 2012


  • In-DTPA- octreotide scintigraphy
  • Cost evaluation


Dive into the research topics of 'Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours'. Together they form a unique fingerprint.

Cite this